A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer

Jhaveri, K; Drago, JZ; Shah, PD; Wang, R; Pareja, F; Ratzon, F; Iasonos, A; Patil, S; Rosen, N; Fornier, MN; Sklarin, NT; Chandarlapaty, S; Modi, S

Modi, S (corresponding author), Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, 300 East 66th St, New York, NY 10065 USA.

CLINICAL CANCER RESEARCH, 2021; 27 (14): 3867

Abstract

Purpose: Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer; however, inhibition of PI3K alone leads to escap......

Full Text Link